United States v. Kenneth Dachman

CourtCourt of Appeals for the Seventh Circuit
DecidedFebruary 18, 2014
Docket13-2353
StatusPublished

This text of United States v. Kenneth Dachman (United States v. Kenneth Dachman) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. Kenneth Dachman, (7th Cir. 2014).

Opinion

In the

United States Court of Appeals For the Seventh Circuit No. 13‐2353

UNITED STATES OF AMERICA, Plaintiff‐Appellee,

v.

KENNETH A. DACHMAN, Defendant‐Appellant.

Appeal from the United States District Court for the Northern District of Illinois, Eastern Division. No. 11‐cr‐00504— James B. Zagel, Judge.

ARGUED JANUARY 9, 2014 — DECIDED FEBRUARY 18, 2014

Before MANION and SYKES, Circuit Judges, and GRIESBACH, District Judge.* MANION, Circuit Judge. Kenneth Dachman was indicted by a grand jury on eleven counts of wire fraud for stealing funds elderly individuals had invested in his three sleep‐related illness‐treatment companies. He pleaded guilty to all eleven

* William C. Griesbach, Chief District Judge for the Eastern District of Wisconsin, sitting by designation. 2 No. 13‐2353

counts and, at sentencing, the district court denied him credit for acceptance of responsibility and sentenced him to 120 months’ incarceration. On appeal, Dachman argues that the district court erred in calculating the loss amount, by denying him credit for acceptance of responsibility, and by imposing an “objectively unreasonable” 120‐month term of imprisonment in light of his severe infirmities. We affirm. I. Factual Background Beginning in June 2008, and continuing until September 2010, Dachman promoted and participated in a scheme to defraud investors. He operated three sleep‐related illness‐ treatment companies and sold shares of these companies to the public. Through his offer and sale of these shares, Dachman raised over $4 million from fifty‐one investors. From the outset, Dachman engaged in a pattern of decep‐ tion. Between July 2008 and January 2009, he falsely repre‐ sented to fifteen investors that their combined invested funds of approximately $1.4 million would be used to operate one of Dachman’s sleep‐treatment companies when, in fact, he had used almost $1 million of those funds for purely personal reasons, including over $200,000 on personal stock trading, over $180,000 on a tattoo parlor, and over $160,000 in checks payable to him and his wife. During this time, the businesses had not yet received any income. But Dachman’s false representations did not begin and end with his deceptions about the status of investments in his sleep‐related illness‐treatment businesses. The falsehoods also pervaded his personal narrative, which was vital to secur‐ ing—and retaining—investors. Dachman represented to No. 13‐2353 3

prospective investors that he personally guaranteed the repayment of their principal, but in reality he did not have the assets to do so. He represented to potential and actual inves‐ tors that he was a successful businessman and researcher when his seven bankruptcies obviously proved otherwise. And he falsely represented to prospective investors and investors that he had obtained a Ph.D. from Northwestern University when in reality he had never even attended that institution. Unsurprisingly, due to Dachman’s deceptions and theft, his companies did not have sufficient revenue to pay the necessary returns to investors. Nor did he have the financial ability to personally guarantee the investors’ principal, contrary to his prior representations. Consequently, the investors brought suit against Dachman and secured judgment in the amount of $2.5 million. Duff v. Dachman, No. 10‐cv‐06162 (N.D. Ill., July 11, 2011). Records reflected that Dachman spent the stolen funds on a tattoo parlor; family vacations and cruises to Italy, Nevada, Florida and Alaska; a new Land Rover; rare books; and to fund personal stock trading and gambling. On July 26, 2011, subsequent to this civil judgment, a federal grand jury returned an eleven‐count indictment charging Dachman with wire fraud. On July 31, 2012, he attempted to enter a plea of nolo contendere. On October 3, 2012, Dachman withdrew his plea and pleaded guilty to all eleven counts of the indictment. Along with his plea, he submitted a plea declaration whereby he admitted that he was “guilty of taking approximately $700,000 dollars in bonuses and fees above reasonable salary”; that he was “guilty of making personal guarantees or returns on investments without sufficient means to support them”; and that he was “guilty of 4 No. 13‐2353

failing to make clear to investors [his] educational and gradu‐ ate credentials.” The district court accepted the guilty plea and set the matter for sentencing. On January 17, 2013, the district court held a sentencing hearing where, among other things, it heard testimony from three victims of Dachman’s fraud. At this hearing, Dachman raised objections to the PSR’s calculation of the guidelines on loss and acceptance of responsibility. With respect to loss, Dachman argued that the correct calculation of the loss amount should be $700,000—the amount by which he personally benefitted—which would result in a 14‐level increase under the guidelines. The government maintained that the proper calculation of the loss amount was approximately $4 million, which would result in an 18‐level guideline increase. The government argued that this number was appropriate because the pool of funds the victims lost by investing with Dachman was $4 million. The district court found that the appropriate loss amount under Guideline § 2B1.1(b) was the approximately $4 million investors lost. Accordingly, the court applied an 18‐level enhancement. The district court also rejected Dachman’s argument that he warranted a two‐level reduction for accep‐ tance of responsibility under Guideline § 3E1.1(a). In his allocution at the sentencing hearing, Dachman claimed he was not the one who asked investors for money, that the business was a success, and that his partner, Scott A. Wolf, was responsible for raising money and communicating with investors. The district court recognized that Dachman stated the “absolute minimum” that qualified him to proceed with a No. 13‐2353 5

guilty plea, but found that he did not “fully accept responsibil‐ ity for the damage he did, for his base motives in doing it[.]” The district court then heard argument from the parties about the appropriate sentence under the factors set forth in 18 U.S.C. § 3553(a). Dachman’s primary argument in mitigation was that the Bureau of Prisons (BOP) was insufficiently equipped to handle his medical conditions. Dachman’s medical conditions include morbid obesity, diabetes, hypertension, hyperlipidemia, severe gout, colon cancer, and coronary artery disease. At sentencing, Dachman’s counsel stated: “[O]ne of the conditions the Court should consider is the necessity for medical treatment.” Dachman’s counsel argued that he required specialists to address his medical issues on a “regular basis” and presented the testimony of his brother, Dr. Carey Dachman, at sentencing. The focus of Dr. Dachman’s testimony was that the BOP only provided physician assistants and that they were ill‐equipped to treat Dachman. Dachman’s counsel expressed his belief that the BOP could not provide adequate life‐sustaining treatment. “The very easy, economic and insurance reason is that malpractice insurance will not cover a specialist doctor going into an inmate population to treat an inmate. That the best Mr. Dachman in prison can expect is to be seen by physician assistants and the occasional visit from a general internist[.]” The government countered that the BOP could provide adequate medical care for Dachman. The government had submitted Dachman’s publicly‐filed medical records to the BOP, and provided the district court with a letter from Dr. Paul Harvey dated October 24, 2012, attached to the PSR, that outlined Dachman’s medical issues and affirmed that the BOP 6 No. 13‐2353

had facilities that could provide the necessary medical treat‐ ment for defendant.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Diekemper
604 F.3d 345 (Seventh Circuit, 2010)
United States v. Ali
619 F.3d 713 (Seventh Circuit, 2010)
United States v. Collins
640 F.3d 265 (Seventh Circuit, 2011)
United States v. Vizcarra
668 F.3d 516 (Seventh Circuit, 2012)
United States v. Roger D. Zehm
217 F.3d 506 (Seventh Circuit, 2000)
United States v. Thomas C. Richardson
238 F.3d 837 (Seventh Circuit, 2001)
United States v. Linda Frykholm
267 F.3d 604 (Seventh Circuit, 2001)
United States v. John D. Conley
291 F.3d 464 (Seventh Circuit, 2002)
United States v. Lavell Dean
414 F.3d 725 (Seventh Circuit, 2005)
United States v. David H. Swanson
483 F.3d 509 (Seventh Circuit, 2007)
United States v. Jwuan Moreland
703 F.3d 976 (Seventh Circuit, 2012)
United States v. Sean Patrick
707 F.3d 815 (Seventh Circuit, 2013)
United States v. Haskins
511 F.3d 688 (Seventh Circuit, 2007)
United States v. Middlebrook
553 F.3d 572 (Seventh Circuit, 2009)
United States v. Verna Pilon
734 F.3d 649 (Seventh Circuit, 2013)
United States v. Anthony Lyons
733 F.3d 777 (Seventh Circuit, 2013)
United States v. Richard Brown
732 F.3d 781 (Seventh Circuit, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. Kenneth Dachman, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-kenneth-dachman-ca7-2014.